Issue Number 574            January 6, 2006


  1. CDC, AAP, and AAFP release the Recommended Childhood and Adolescent Immunization Schedule for 2006


Back to Top


(1 of 1)
January 6, 2006

CDC, AAP, and AAFP have endorsed and released the Recommended Childhood and Adolescent Immunization Schedule--United States, 2006. On January 6, CDC published the schedule as an MMWR QuickGuide; a portion of the text is reprinted below.

Additional materials. AAP published an article about the 2006 schedule in the January 2006 issue of the journal Pediatrics. The AAFP website posted information and a 2-page version of the 2006schedule. CDC issued a press release about the schedule. Links to the Pediatrics article, the AAFP information and 2-page schedule, and the CDC press release are given at the end of this IAC Express issue.


The Advisory Committee on Immunization Practices (ACIP) periodically reviews the recommended childhood and adolescent immunization schedule to ensure that the schedule is current with changes in vaccine formulations and reflects revised recommendations for the use of licensed vaccines, including those newly licensed. The recommendations and format of the childhood and adolescent immunization schedule and catch-up schedule for January-December 2006 were approved by ACIP, the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).

The changes to the previous childhood and adolescent immunization schedule, published January 2005, are as follows:

  • The importance of the hepatitis B vaccine (HepB) birth dose has been emphasized. Vaccination of infants born to hepatitis B surface antigen (HBsAg)-negative mothers can be delayed in rare circumstances, but only if a physician's order to withhold the vaccine and a copy of the mother's original HBsAg-negative laboratory report are documented in the infant's medical record. Administering four doses of HepB is permissible (e.g., when combination vaccines are administered after the birth dose); however, if monovalent HepB is used, a dose at age 4 months is not needed. For infants born to HBsAg-positive mothers, testing for HBsAg and antibody to HBsAg after completion of the vaccine series should be conducted at age 9-18 months (generally at the next well-child visit after completion of the vaccine series).
  • A new tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine recommended by ACIP for adolescents (Tdap adolescent preparation) was approved by the Food and Drug Administration (FDA) on May 5, 2005, for use in the United States. Tdap is recommended for adolescents aged 11-12 years who  have completed the recommended childhood diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP) vaccination series and have not received a tetanus and diphtheria toxoids (Td) booster dose. Adolescents aged 13-18 years who missed the age 11-12-year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series. Subsequent Td boosters are recommended every 10 years.
  • Meningococcal conjugate vaccine (MCV4), approved by FDA on January 14, 2005, should be administered to all children at age 11-12 years as well as to unvaccinated adolescents at high school entry (age 15 years). Other adolescents who wish to decrease their risk for meningococcal disease may also be vaccinated. All college freshmen living in dormitories should also be vaccinated with MCV4 or meningococcal polysaccharide vaccine (MPSV4). For prevention of invasive meningococcal disease, vaccination with MPSV4 for children aged 2-10 years and with MCV4 for older children in certain high-risk groups is recommended.
  • Influenza vaccine is now recommended for children aged 6 months [and older] with certain risk factors, which now specifically include conditions that can compromise respiratory function or handling of respiratory secretions or that can increase the risk for aspiration.
  • Hepatitis A vaccine is now universally recommended for all children at age 1 year (12-23 months). The 2 doses in the series should be administered at least 6 months apart.
  • The catch-up schedule for persons aged 7-18 years has been changed for Td; Tdap may be substituted for any dose in a primary catch-up series or as a booster if age appropriate for Tdap. A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose.

Vaccine Information Statements
The National Childhood Vaccine Injury Act requires that healthcare providers provide parents or patients with copies of Vaccine Information Statements before administering each dose of the vaccines listed in the schedule. Additional information is available from state health departments and from CDC at

Detailed recommendations for using vaccines are available from package inserts, ACIP statements on specific vaccines, and the 2003 Red Book. ACIP statements for each recommended childhood vaccine are available at the CDC National Immunization Program website at In addition, guidance for obtaining and completing a Vaccine Adverse Event Reporting System form is available at or by telephone, (800) 822-7967.


To access a web-text (HTML) version of the complete MMWR article, go to:

To access a ready-to-print (PDF) version of the MMWR QuickGuide, go to:

AAP. In the January 2006 issue of Pediatrics, AAP published Recommended Childhood and Adolescent Immunization Schedule--United States, 2006 as a policy statement from its Committee on Infectious Diseases.

To access a ready-to-print (PDF) version of the article, go to:

To access a web-text (HTML) version of it, go to:

AAFP. AAFP recently posted a brief page of information about the 2006 schedule, as well as a link to a two-page version of the schedule.

To access the page of material, go to:

To access a ready-to-print (PDF) version of a two-page 2006 schedule, go to:

CDC. On January 5, CDC issued a press release, "Recommended Childhood and Adolescent Immunization Schedule--United States, 2006."

To access the press release, go to:

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .